Wellgistics Appoints New CTO Amid Deep Distress; No Change to Bearish Thesis

What happened

Wellgistics Health announced the appointment of Brett Thompson as consulting Chief Technology Officer, a veteran health IT executive with over 30 years of experience. The move comes as the company grapples with severe liquidity issues, a going-concern warning, and a 47% revenue decline in Q3 2025. While Thompson's expertise could support the EinsteinRx and PharmacyChain platforms, the company's financial distress—$24.8M in debt, negative operating cash flow, and reliance on dilutive financing—remains the dominant risk. The executive addition does nothing to address the immediate survival challenges or the lack of disclosed revenue or adoption metrics for its key technology initiatives. Without a clear path to refinancing or tangible platform traction, the equity remains a speculative option rather than a fundamental investment.

Implication

For long-term investors, this hire alone cannot shift the risk-reward skew. The company must first resolve its going-concern issue through refinancing or demonstrable revenue from EinsteinRx/Brenzavvy. Continue to avoid until evidence of sustainable funding and platform traction emerges.

Thesis delta

The appointment of a seasoned health IT CTO is a marginal positive for the platform story but does not change the underlying thesis. Wellgistics remains a deeply distressed entity where survival and dilution risks dominate any potential upside. The bear case (50% probability of material capital loss) still outweighs the bull case (15% probability of modest recovery). Confidence in the STRONG SELL conviction remains high at 4.5/5.